A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00344721|
Recruitment Status : Unknown
Verified June 2006 by University of Texas Southwestern Medical Center.
Recruitment status was: Recruiting
First Posted : June 27, 2006
Last Update Posted : June 27, 2006
|Condition or disease||Intervention/treatment||Phase|
|Dry Eye Syndrome||Drug: Essential fatty acid supplement||Phase 4|
The effects of essential fatty acids on Meibomian Gland lipid composition and aqueous tear production may be greater than previously thought. Dry Eye syndromes afflict millions of people worldwide, more than 10 million in the United States alone. Typically, symptoms that are associated with dry eye disease include ocular burning, foreign body sensation, photophobia and other symptoms that result in overall chronic discomfort in patients. Unfortunately, the effects of Essential Fatty Acids on aqueous tears or Meibomian lipids (AT) have not been established to date. The purpose of this study is to better understand the role essential fatty acids play in the maintenance of meibomian gland lipids and overall production or retention of aqueous tears.
Patients diagnosed with dry eye syndrome will be selected to participate in the study. Once qualified to take part in the trial, participants will receive four oral doses of soft-gel capsules to be taken daily (QD). Omega-3 Fatty Acid tablet contains:
EPA (eicosapentaenoic acid) Dose: 450mg DHA (docosahexaenoic acid) Dose: 300mg Flaxseed Oil (organic) Dose: 1000mg
Patients on placebo will receive nutritional supplements containing wheat germ oil but no EFA’s. During the trial, patient will be encouraged not to change their diet, use of topical ophthalmics and systemic therapies other than the use of study treatment. Patient’s topical therapy will be standardized after identification exam so that all patients will use TheraTears™ four times daily. Patients will be directed to take the masked capsules in the following manner: 4 soft-gels in the morning.
Masked medication, TheraTears™ and randomization tables will be provided by sponsor.
Subject will have the following tests performed during the first visit (before initiating treatment) and follow-up (after three months of treatment) visit,: a complete eye exam, (vital staining of ocular surface and tear break-up time); completion of questionnaires: Ocular Surface Index (OSDI) and Patient Symptomology Questionnaire will be presented to the patient to review and answer at both visits: Before initiating treatment and after three months on therapy, meibography, fluorophotometry will be performed in order to measure tear volume, flow and turnover, Schirmer test; and tear evaporation using an evaporometer; meibomian gland drop out determined by infrared photography and meibomian gland secretion for biochemical analysis.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome|
|Study Start Date :||September 2004|
|Study Completion Date :||June 2006|
- Lipid biochemistry changes pre and post treatment with masked treatment
- Evaporametry and Fluorophometry changes pre and post treatment with masked treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00344721
|Contact: Mike Molai, B.S.||214-648-4734||Mike.Molai@UTSouthwestern.edu|
|United States, Texas|
|University of Texas Southwestern Medical Center at Dallas||Recruiting|
|Dallas, Texas, United States, 75390-8866|
|Contact: Mike Molai, B.S. 214-648-4734 Mike.Molai@UTSouthwestern.edu|
|Principal Investigator: James P. McCulley, M.D.|
|Sub-Investigator: Igor Butovich, Ph.D.|
|Sub-Investigator: Joel D. Aronowicz, M.D.|
|Principal Investigator:||James P. McCulley, M.D.||University of Texas, Southwestern Medical Center at Dallas|